IMMURON LIMITED (IMMU) Form 6-K Summary
- Critical Regulatory Update: Immuron Limited announced receipt of FDA approval for the Investigational New Drug (IND) application for its drug candidate, IMM-529.
- This milestone, disclosed November 5, 2025, clears the path for the Company to commence U.S. clinical trials for IMM-529.
- > This approval represents a significant step forward in the development pipeline for IMM-529.
Filing context: This Form 6-K serves to file the corresponding announcement made to the Australian Securities Exchange (ASX).